AI assistant
BICO Group — Capital/Financing Update 2025
Feb 18, 2025
2891_iss_2025-02-18_dd519bbe-9106-4f21-9480-aba7ce340802.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 276m
On March 19, 2021, BICO Group AB (publ) ("BICO" or the "Company") issued senior unsecured convertible bonds with a total nominal amount of SEK 1,500,000,000 (the "Convertible Bonds").
On February 18, 2025, the Company repurchased Convertible Bonds with a total nominal amount of SEK 276,000,000 at a purchase price of 89.4719 percent (excluding accrued but unpaid interest) of the Convertible Bond's nominal amount. The total purchase consideration for the bought-back Convertible Bonds thereby amounted to SEK 246,942,500 (the "Buyback"). Following the Buyback, and together with the Convertible Bonds repurchased by BICO on 22 November 2024 (as separately communicated), the total nominal amount of repurchased Convertible Bonds by BICO totals SEK 394,000,000 leaving SEK 1,106,000,000 in Convertible Bonds outstanding.
The rationale behind the Buyback was to optimize BICO's capital structure and made possible by the Company's strong liquidity position. BICO will continue to evaluate the bond market and may from time to time repurchase further Convertible Bonds in the market, subject to the liquidity needs of the Company.
The Buyback was conducted through a safe harbour approach with Carnegie Investment Bank AB (publ) as Dealer Manager.
For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB Phone: +46 735 34 88 84 E-mail: [email protected]
This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-18 17:42 CET.
About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,900 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
Attachments
BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 276m